Giant ovarian tumors (GOTs) are uncommon ovary neoplasms with no universally accepted definition. They are typically noncancerous, with a mucinous subtype being the most common characteristic. Epithelial ovarian tumors are classified by cell type into serous, endometrioid, clear cell, mucinous, seromucinous, or transitional. Seromucinous cystadenomas are largely asymptomatic and can present with massive dimensions in late diagnoses, especially in low‐to‐middle‐income regions. In this case, a 26‐year‐old nulliparous Arab woman presented with a giant ovarian cyst in her reproductive age, undiagnosed for 9 years, which turned out to be a benign histopathology of seromucinous cystadenoma. The clinical presentation was nonspecific, as large ovarian cysts are often asymptomatic until they reach a substantial size to affect the quality of life and fertility. She had progressive abdominal swelling first noticed 6 years ago, but she started developing a feeling of fullness, constipation, nausea, vomiting, and urinary hesitancy with painful micturition 5 months prior to presentation with marked distress. The cystadenoma was excised without complications, through the exploratory laparotomy, and a left salpingo‐oophorectomy with right cystectomy was performed. Seromucinous cystadenomas were first classified in 2014 by the World Health Organization (WHO) as a new entity and a rare subtype of ovarian epithelial tumors. Patients with benign seromucinous cystadenomas have an excellent prognosis, especially with complete surgical removal. Raising awareness and increasing access to gynecological care in low‐ and middle‐income countries are essential for the long‐term well‐being and health of patients with giant ovarian cysts.
Kakeh et al. (Thu,) studied this question.